DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
206	脆弱X症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01517698 (ClinicalTrials.gov)	May 2012	20/1/2012	A Study of RO4917523 in Patients With Fragile X Syndrome	A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.	Fragile X Syndrome	Drug: Placebo;Drug: RO4917523 0.5 mg;Drug: RO4917523 1.5 mg	Hoffmann-La Roche	NULL	Completed	14 Years	50 Years	Both	185	Phase 2	United States;Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01517698
(ClinicalTrials.gov)

May 2012

20/1/2012

A Study of RO4917523 in Patients With Fragile X Syndrome

A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.

Fragile X Syndrome

Drug: Placebo;Drug: RO4917523 0.5 mg;Drug: RO4917523 1.5 mg

Hoffmann-La Roche

NULL

Completed

14 Years

50 Years

Both

185

Phase 2

United States;Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom